[Growth suppression of subcutaneous tumor by CT26 expressing NK4 in syngeneic mice]

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Context:

• Hepatocyte growth factor (HGF) and its receptor MET signaling pathways are crucial in tumor progression, driving invasion, metastasis, and angiogenesis.
• NK4 is a potent antagonist of HGF-Met receptor binding, exhibiting potential antitumor activities.

Purpose:

• To investigate the antitumor effects of NK4 by examining the biological behaviors of CT26 cells genetically modified to express NK4 (CT26-NK4) both in vitro and in vivo.
• To elucidate the mechanisms underlying NK4's antitumor activity, specifically comparing its effects on tumor cell invasion and angiogenesis.

Summary:

• In vitro studies showed NK4 completely inhibited HGF-stimulated tumor cell invasion.
• In vivo experiments demonstrated that CT26-NK4 tumors exhibited significantly suppressed growth and prolonged survival in tumor-bearing mice.
• Immunohistochemical analysis revealed that NK4 significantly reduced tumor micro-vessel density (CD31/PECAM-1 staining) with only minor suppression of proliferating cells (PCNA staining).

Impact:

• NK4 demonstrates potent antitumor efficacy primarily through anti-angiogenic mechanisms, rather than direct inhibition of HGF-stimulated tumor cell biological events.
• These findings highlight NK4 as a promising therapeutic agent targeting tumor angiogenesis for cancer treatment.
• The study provides a mechanistic understanding of NK4's action, emphasizing its role in disrupting tumor vascularization.